A curing agent composition contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C., and at least one halo-substituted diethyltoluenediamine, in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. A curable resin composition contains at least one epoxy compound having at least two epoxide groups per molecule of the epoxy compound and the curing agent composition. Methods for inhibiting phase separation of a curing agent composition or curable resin composition that contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C. include a step of adding to the respective composition at least one halo-substituted diethyltoluenediamine in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. The compositions and methods are useful in making fiber reinforced resin matrix composite articles.

The invention relates to purely organic emitter molecules of a new type according to formula I and to the use thereof in optoelectronic devices, in particular in organic light-emitting diodes (OLEDs), comprising donor D: an aromatic or heteraromatic chemical group on which the HOMO is located and which optionally has at least one substitution; acceptor A: an aromatic or heteromatic chemical group on which the LUMO is located and which optionally has at least one substitution; bridge B1, bridge B2: organic groups that link the donor D and the acceptor A in a non-conjugated manner; wherein in particular the energy difference ΔE(S.sub.1−T.sub.1) between the lowest excited singlet (S1) state of the organic emitter molecule and the triplet (T1) state of the organic emitter molecule lying thereunder is less than 2000 cm.sup.−1.

The invention relates to purely organic emitter molecules of a new type according to formula I and to the use thereof in optoelectronic devices, in particular in organic light-emitting diodes (OLEDs), comprising donor D: an aromatic or heteraromatic chemical group on which the HOMO is located and which optionally has at least one substitution; acceptor A: an aromatic or heteromatic chemical group on which the LUMO is located and which optionally has at least one substitution; bridge B1, bridge B2: organic groups that link the donor D and the acceptor A in a non-conjugated manner; wherein in particular the energy difference ΔE(S.sub.1−T.sub.1) between the lowest excited singlet (S1) state of the organic emitter molecule and the triplet (T1) state of the organic emitter molecule lying thereunder is less than 2000 cm.sup.−1.

Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

The invention belongs to the technical field of pesticides and specifically relates to an aryl sulfide containing a benzylamine structure, a synthesis method therefor, and an application thereof. The aryl sulfide is denoted as compound I. Also provided is an agriculturally acceptable salt of the aryl sulfide. The compound represented by formula I shows excellent effects on various harmful organisms, especially spider mites represented by Tetranychus cinnabarinus, Tetranychus urticae, Tetranychus Kanzawai Kishida, Panonychus citri, etc., and can be used for controlling all kinds of harmful mites.